SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Patient Survival Outcomes Post-Surgery

SURGE Therapeutics, a biotech company headquartered in Cambridge, Massachusetts, has secured $32 million in Series B financing to advance its intraoperative immunotherapy programs. Leading the funding round is Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and existing investors. &nbsp The raised funds will be utilized to support the clinical development of SUR..

• format_list_bulleted Pharmacology/BS
• · 2023. 7. 19.
• textsms

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease

Vaxxinity has announced that its Phase 1 clinical trial of the investigational vaccine UB-312 for Parkinson's disease (PD) has met primary objectives. The vaccine was immunogenic in patients with early PD and generally safe and well-tolerated, demonstrating potential as a candidate for the prevention or modification of PD. UB-312 is an investigational synthetic peptide vaccine that targets toxic..

• format_list_bulleted Pharmacology/BS
• · 2023. 6. 23.
• textsms

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor

Tvardi Therapeutics has announced that the first patients have been dosed in each arm of its REVERT LIVER CANCER trial, which is evaluating TTI-101 as monotherapy and in combination with standard of care therapy for liver cancer. The trial is designed to evaluate TTI-101 across multiple lines of therapy and is currently enrolling HCC patients at top US cancer research institutes. Liver cancer is..

• format_list_bulleted Pharmacology/BS
• · 2023. 6. 23.
• textsms